Chemical Namemidostaurin
Dosage FormCapsule (oral; 25 mg)
Drug ClassKinase inhibitors
Approval Year2017


  • To treat newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive in adults.
  • To treat aggressive systemic mastocytosis in adults.
  • To treat systemic mastocytosis with associated hematological neoplasm in adults.
  • To treat mast cell leukemia in adults.
Last updated on 11/2/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Rydapt (Midostaurin) Prescribing Information2017Novartis Pharmaceuticals Corporation, East Hanover, NJ
Document TitleYearSource
Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology. 2019Journal of the National Comprehensive Cancer Network